Evidence map›Paper›PMID 39822038›Full record

ArticleJournal of medical virology2025

A 10 Year Long-Lived Cellular and Humoral MERS-CoV Immunity Cross-Recognizing the Wild-Type and Variants of SARS-CoV-2: A Potential One-Way MERS-CoV Cross-Protection Toward a Pan-Coronavirus Vaccine.

Bandar Alosaimi, Maaweya Awadalla, Wael Alturaiki, Zhao Chen, Zhaoyong Zhang, Airu Zhu, Fatimah Rebh, Abeer N Alshukairi, Jincun Zhao, Haitham S Alkadi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bandar AlosaimiResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.ORCID 0000-0003-4719-2655
Maaweya AwadallaResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.ORCID 0000-0002-1270-2216
Wael AlturaikiDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah, Riyadh Region, Saudi Arabia.
Zhao ChenState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhaoyong ZhangState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Airu ZhuState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Fatimah RebhDepartment of Internal Medicine, Section of Infectious Diseases, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
Abeer N AlshukairiDepartment of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Jincun ZhaoState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Haitham S AlkadiResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia.

Funding

This study was funded by the Research Center at King Fahad Medical City (Grant No. IRF 019-058).
6 · The paper itself

Abstract

MERS is a respiratory disease caused by MERS-CoV. Multiple outbreaks have been reported, and the virus co-circulates with SARS-CoV-2. The long-term (> 6 years) cellular and humoral immune responses to MERS-CoV and their potential cross-reactivity to SARS-CoV-2 and its variants are unknown. We comprehensively investigated long-lasting MERS-CoV-specific cellular and humoral immunity, and its cross-reactivity against SARS-CoV-2 and its variants, in individuals recovered from MERS-CoV infection 1-10 years prior. Two cohorts of MERS-CoV survivors (31 unvaccinated, 38 COVID-19 vaccinated) were assessed for MERS-CoV IgG, memory CD4

Indexed as

Cross ProtectionImmunity, CellularImmunity, HumoralMiddle East Respiratory Syndrome CoronavirusSARS-CoV-2Viral VaccinesAdultAgedAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesCross ReactionsFemaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GViral VaccinesBA.5 variantcellular immunitycross‐reactivityDelta varianthumoral immunityMERS‐CoVSARS‐CoV‐2short‐term T cell line

Identifiers

PMID39822038
PMCPMC11740004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.